Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific working party on functional dyspepsia

被引:48
作者
Talley, NJ [1 ]
Lam, SK
Goh, KL
Fock, KM
机构
[1] Univ Sydney, Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia
[2] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China
[3] Univ Malaya, Kuala Lumpur, Malaysia
[4] Univ Hosp, Kuala Lumpur, Malaysia
[5] Natl Univ Singapore, Fac Med, Singapore 117548, Singapore
[6] New Changi Hosp, Singapore, Singapore
关键词
antisecretory cisapride; domperidone; endoscopy; functional dyspepsia; H-2; blocker; H-pylori; management trials; non-ulcer dyspepsia; prokinetic; proton pump inhibitor;
D O I
10.1111/j.1440-1746.1998.tb00644.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Dyspepsia is most optimally defined as pain or discomfort centred in the upper abdomen. The symptom complex may be caused by peptic ulcer disease, gastro-oesophageal reflux, or gastric cancer but is most often due to functional (or non-ulcer) dyspepsia. While upper endoscopy is the method of choice to determine the underlying cause of dyspepsia, it is expensive. A more pragmatic approach is needed in the Asia-Pacific region where health services are limited. A detailed treatment algorithm is given for managing patients presenting with new-onset dyspepsia and documented functional dyspepsia after endoscopy, and evidence to support this approach is reviewed. Prompt endoscopy is recommended for patients with alarm fea-tures. In patients without alarm features, treatment for 2-4 weeks with an empirical anti-secretory or prokinetic agent, followed by investigation using non-invasive Helicobacter pylori testing and treatment for patients who do not respond or relapse, is recommended. Trials of management strategies are now needed to establish the efficacy and cost-effectiveness of the approaches recommended.
引用
收藏
页码:335 / 353
页数:19
相关论文
共 123 条
[51]  
Holtmann G, 1996, AM J GASTROENTEROL, V91, P485
[52]  
HOTZ J, 1994, MED KLIN, V89, P73
[53]  
HUI WM, 1991, AM J GASTROENTEROL, V86, P292
[54]  
HUNGIN APS, 1994, BRIT J GEN PRACT, V44, P519
[55]   DYSPEPSIA AND DYSPEPSIA SUBGROUPS IN JAPAN - SYMPTOM PROFILES AND EXPERIENCE WITH CISAPRIDE [J].
INOUE, M ;
SEKIGUCHI, T ;
HARASAWA, S ;
MIWA, T ;
MIYOSHI, A .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1993, 28 :36-39
[56]  
Jebbink H J, 1993, Ned Tijdschr Geneeskd, V137, P1772
[57]   THE SYMPTOMATIC EFFECT OF 1-DAY TREATMENT PERIODS WITH CIMETIDINE IN DYSPEPSIA - COMBINED RESULTS FROM RANDOMIZED, CONTROLLED, SINGLE-SUBJECT TRIALS [J].
JOHANNESSEN, T ;
KRISTENSEN, P ;
PETERSEN, H ;
FOSSTVEDT, D ;
LOGE, I ;
KLEVELAND, PM ;
DYBDAHL, J .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 (09) :974-980
[58]   CIMETIDINE ON-DEMAND IN DYSPEPSIA - EXPERIENCE WITH RANDOMIZED CONTROLLED SINGLE-SUBJECT TRIALS [J].
JOHANNESSEN, T ;
PETERSEN, H ;
KRISTENSEN, P ;
FOSSTVEDT, D ;
KLEVELAND, PM ;
DYBDAHL, J ;
LOGE, I .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (03) :189-195
[59]  
JONES R, 1992, BRIT J CLIN PRACT, V46, P95
[60]   Lansoprazole 30 mg daily versus ranitidine 150 mg bd in the treatment of acid-related dyspepsia in general practice [J].
Jones, RH ;
Baxter, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 (03) :541-546